Cancer genome sequencing studies indicate that a single breast cancer typically harbours multiple genetically distinct subclones [1] [2] [3] [4] . As carcinogenesis involves a breakdown in the cell-cell cooperation that normally maintains epithelial tissue architecture, individual subclones within a malignant microenvironment are commonly depicted as selfinterested competitors 5,6 . Alternatively, breast cancer subclones might interact cooperatively to gain a selective growth advantage in some cases. Although interclonal cooperation has been shown to drive tumorigenesis in fruitfly models 7,8 , definitive evidence for functional cooperation between epithelial tumour cell subclones in mammals is lacking. Here we use mouse models of breast cancer to show that interclonal cooperation can be essential for tumour maintenance. Aberrant expression of the secreted signalling molecule Wnt1 generates mixed-lineage mammary tumours composed of basal and luminal tumour cell subtypes, which purportedly derive from a bipotent malignant progenitor cell residing atop a tumour cell hierarchy 9 . Using somatic Hras mutations as clonal markers, we show that some Wnt tumours indeed conform to a hierarchical configuration, but that others unexpectedly harbour genetically distinct basal Hras mutant and luminal Hras wild-type subclones. Both subclones are required for efficient tumour propagation, which strictly depends on luminally produced Wnt1. When biclonal tumours were challenged with Wnt withdrawal to simulate targeted therapy, analysis of tumour regression and relapse revealed that basal subclones recruit heterologous Wnt-producing cells to restore tumour growth. Alternatively, in the absence of a substitute Wnt source, the original subclones often evolve to rescue Wnt pathway activation and drive relapse, either by restoring cooperation or by switching to a defector strategy. Uncovering similar modes of interclonal cooperation in human cancers may inform efforts aimed at eradicating tumour cell communities.
Cancer genome sequencing studies indicate that a single breast cancer typically harbours multiple genetically distinct subclones [1] [2] [3] [4] . As carcinogenesis involves a breakdown in the cell-cell cooperation that normally maintains epithelial tissue architecture, individual subclones within a malignant microenvironment are commonly depicted as selfinterested competitors 5, 6 . Alternatively, breast cancer subclones might interact cooperatively to gain a selective growth advantage in some cases. Although interclonal cooperation has been shown to drive tumorigenesis in fruitfly models 7, 8 , definitive evidence for functional cooperation between epithelial tumour cell subclones in mammals is lacking. Here we use mouse models of breast cancer to show that interclonal cooperation can be essential for tumour maintenance. Aberrant expression of the secreted signalling molecule Wnt1 generates mixed-lineage mammary tumours composed of basal and luminal tumour cell subtypes, which purportedly derive from a bipotent malignant progenitor cell residing atop a tumour cell hierarchy 9 . Using somatic Hras mutations as clonal markers, we show that some Wnt tumours indeed conform to a hierarchical configuration, but that others unexpectedly harbour genetically distinct basal Hras mutant and luminal Hras wild-type subclones. Both subclones are required for efficient tumour propagation, which strictly depends on luminally produced Wnt1. When biclonal tumours were challenged with Wnt withdrawal to simulate targeted therapy, analysis of tumour regression and relapse revealed that basal subclones recruit heterologous Wnt-producing cells to restore tumour growth. Alternatively, in the absence of a substitute Wnt source, the original subclones often evolve to rescue Wnt pathway activation and drive relapse, either by restoring cooperation or by switching to a defector strategy. Uncovering similar modes of interclonal cooperation in human cancers may inform efforts aimed at eradicating tumour cell communities.
Cancer progression is known to depend on cooperation between tumour cells and neighbouring host cells in the microenvironment. Some have suggested that cooperation between distinct tumour cell subsets may also contribute to the malignant phenotype [10] [11] [12] . Favouring this possibility, genetically distinct subclones cooperatively enhanced tumour growth in models engineered to recapitulate a form of tumour cell heterogeneity identified in brain cancers 13 . Similarly, phenotypically distinct tumour cell subsets cooperatively enhanced tumour invasion in a murine lung cancer model 14 . In the case of human breast cancer, recent studies highlight the phenotypic and genetic diversity present locally within individual tumours 15, 16 , but whether this heterogeneity is a cause or a consequence of tumour progression remains unclear. Accordingly, we sought definitive evidence for functional cooperation between tumour cell subsets in mouse models of human breast cancer.
Mammary cancers arising in the classic mouse mammary tumour virus (MMTV)-Wnt1 transgenic mouse model 17 display tumour cell heterogeneity that is widely attributed to malignant transformation of a bipotent mammary progenitor cell 9, 18, 19 . Concordantly, MMTV-Wnt1 tumour cells partition into basal and luminal subsets which comingle, recalling the corresponding basal and luminal lineages found in the normal mammary gland (Fig. 1a, b ). Although mutations in Wnt pathway components are rare in human breast cancers, the transcriptional profile of Wnt1-initiated tumours resembles that of other mammary cancer models that commonly show mixed-lineage histopathology, including chemical carcinogen-induced rodent mammary cancers 20, 21 .
While studying cooperating oncogenic mutations in the MMTV-Wnt1 model, we found evidence suggesting that some Wnt tumours harbour unexpected genetic heterogeneity. About half of all Wnt-initiated mammary tumours spontaneously acquire somatic Hras mutations that encode an activated oncoprotein 22, 23 . Because Hras mutations act dominantly, Hras mutant allele fractions (MAFs) of approximately 0.5 are expected, barring copy number changes at the Hras locus. Instead, when tumour-derived Hras alleles were amplified by PCR and subjected to DNA sequencing, chromatogram peak heights often indicated smaller Hras MAFs, with fractions ,0.3 detected in four out of ten tumours. Notably, tumours maintained their small Hras MAFs as a stable property when explanted onto the flanks of syngeneic host mice ( Fig. 1c ). This discrepancy could not be explained by contamination of samples with normal (non-tumour) cells as tumour cell content assessed by histopathology consistently exceeded 80%. Moreover, copy number variations leading to either Hras wild-type (Hras wt ) allele gain or Hras mutant (Hras mut ) allele loss seemed unlikely driver events. Instead, we considered whether some Wnt tumours might harbour distinct Hras mut and Hras wt subclones, noting that biclonal tumours would adopt a mixedlineage phenotype provided each subclone were committed to a distinct lineage.
To search for lineage-restricted Hras mut and Hras wt subclones, dissociated cells prepared from Hras mut Wnt tumours were sorted into basal and luminal subsets (Extended Data Fig. 1 ), then Hras MAFs were determined for each subset and for corresponding samples of unsorted cells. Half of the Hras mut Wnt tumours analysed (five out of ten) showed negligible subset-specific enrichment in Hras mut alleles, a pattern consistent with a hierarchical configuration ( Fig. 1d, e ). In these cases, basal and luminal cells from the same tumour always harboured identical Hras mut alleles ( Fig. 1e ), suggesting that they descended from a common bipotent Hras mut progenitor. By contrast, for the remaining half of tumours analysed, Hras mut alleles were highly enriched within the basal tumour cell subset, a pattern consistent with a biclonal configuration ( Fig. 1e ). Basal Hras mut allele enrichment correlated with a lower overall Hras MAF, further suggesting the presence of a private, subclonerestricted mutation. Regardless of whether the distribution of Hras mut alleles fits a hierarchical or biclonal pattern, tumours showed classic mixed-lineage histopathology (Extended Data Fig. 2 ), and luminal tumour cells were invariably the main source of Wnt1 expression as reported previously 24 (Fig. 1f ). Therefore, some Wnt tumours appeared to harbour distinct basal Hras mut Wnt1 low and luminal Hras wt Wnt1 high subclones, implicating interclonal cooperation in tumour maintenance. These findings recall early reports in which MMTV-associated mammary tumours initiated by activation of endogenous Wnt genes were sometimes noted to be oligoclonal 25, 26 .
Seeking stringent proof that some Wnt tumours are biclonal and require interclonal cooperation for maintenance, we attempted to rescue growth of basal Hras mut Wnt1 low subclones from Wnt1 deprivation by providing access to replacement Wnt1-producing cells. For these experiments, the original MMTV-Wnt1 model (hereafter termed cWnt, denoting constitutive Wnt1 expression) was used in combination with a closely related model engineered for doxycycline (Dox)-dependent transgene expression (MMTV-rtTA/Tet-O-Wnt1; hereafter termed iWnt, denoting inducible Wnt1 expression). During chronic Dox treatment, iWnt mice and mammary tumours phenocopy their cWnt counterparts, but iWnt tumours regress following Dox withdrawal owing to abrogation of Wnt1 transgene expression 27 . To enable tracking of cell lineages in tumour reconstitution experiments, iWnt mice were crossed with a monomeric red fluorescent protein (mRFP) reporter line, generating iWnt/mRFP 1 mice. As expected, a subset of Dox-dependent iWnt/ mRFP 1 mammary tumours appeared to be biclonal, as they harboured a basally restricted Hras mut subclone. After dissociating these tumours into cell suspensions, 10 5 unsorted cells were injected orthotopically into the mammary fat pads of two sets of Dox-treated, mRFP-reporternegative female host mice ( Fig. 2a ). Control hosts lacked a transgene capable of rescuing tumour cells from Wnt withdrawal (wt/mRFP 2 ), whereas rescue hosts expressed the constitutive Wnt1 transgene (cWnt/mRFP 2 ).
During chronic Dox treatment, both control and rescue hosts developed mammary tumours in most glands injected with iWnt/mRFP 1 tumour cells ( Fig. 2b and Extended Data Table 1 ). As expected, these reconstituted tumours usually regressed when iWnt transgene expression was switched off via Dox withdrawal. On control hosts, tumour regression was always complete, and mice remained relapse-free during 6 weeks of monitoring. Interestingly, subclinical disease often persisted, as most control hosts subsequently relapsed after Dox retreatment ( Fig. 2b) . By contrast, on cWnt rescue hosts, most reconstituted tumours only partially regressed, then relapsed spontaneously ( Fig. 2b and Extended Data Fig. 3a ). On control hosts, primary tumours were reconstituted almost exclusively from donor mRFP 1 cells, and relapses triggered by Dox retreatment remained mRFP 1 as expected ( Fig. 2c ). By contrast, on rescue hosts primary tumours showed varying degrees of chimaerism due to incorporation of mRFP 2 (host-derived) luminal cells (Extended Data Fig. 3b ), and relapses arising during Dox withdrawal always showed pronounced lineage-restricted chimaerism, resulting in mRFP 1 /basal and mRFP 2 /luminal subpopulations ( Fig. 2c ). To confirm that donor basal subclones recruit host luminal epithelium to serve as a replacement Wnt1 source at relapse, we turned to northern hybridization analysis of tumour RNAs. Notably, tumours reconstituted on rescue hosts typically expressed the larger iWnt transgene before Dox withdrawal (pertinent exceptions discussed in Extended Data Fig. 3 ), then switched to expressing the smaller cWnt transgene at relapse, indicating heterologous rescue ( Fig. 2d ).
Furthermore, the biclonal configuration evident in parental tumours was maintained in all reconstituted tumours in that basal cells were Hras mut Wnt1 low , whereas luminal cells were Hras wt Wnt1 high (Extended Data Fig. 4 ). We repeated these rescue experiments twice, beginning each time with an independent, iWnt/mRFP tumour harbouring a distinct, basally restricted Hras mutation. In all cases, we observed rescue of donor-derived basal Hras mut Wnt1 low tumour cells by cWnt hostderived luminal Hras wt Wnt1 high cells (Fig. 3a, b and Extended Data Fig. 5 ). Moreover, the Hras mut allele detected in relapsed tumours was always identical to that detected in parental tumours, confirming that basal subclones found at relapse were descended from donor-derived tumour cells and were not novel clones. Examination of tumour sections by fluorescence microscopy revealed pervasive intermingling of basal mRFP 1 and luminal mRFP 2 tumour cells within chimaeric relapses, consistent with the prevailing notion that secreted Wnt provides a shortrange signal to neighbouring cells ( Fig. 3c ). Prospective analysis of a larger set of independent Wnt tumours will be required to precisely estimate the overall fraction of Wnt tumours that is biclonally configured. Notably, we cannot yet determine clonal configurations for the half of Wnt tumours that lack an Hras mutation.
Whereas biclonal iWnt/mRFP 1 tumours were readily reconstituted from unsorted (fluorescence-activated cell sorting (FACS)-naive) cells, sorted basal and luminal cells each reconstituted tumours inefficiently when injected into mammary glands (Extended Data Fig. 6a ), perhaps 
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owing in part to loss of cell viability during FACS. Notably, tumours that did arise after injecting a single sorted subtype were always biclonal, comprised of both basal Hras mut Wnt1 low and luminal Hras wt Wnt1 high subsets (seven out of seven tumours analysed, Extended Data Fig. 6b ). Given the imperfect separation achieved by FACS (95-98% purity), rare cells cross-contaminating each subset presumably sufficed to permit interclonal cooperation during tumour reconstitution. Consistent with this notion, the relative sizes of the basal and luminal cell populations within these tumours approximated that found in parental tumours and did not reflect the lineage enrichment achieved by sorting. We confirmed this result in an experimental context where the putative cooperating subclones were differentially labelled by the mRFP transgene.
Here, tumour cells derived from chimaeric relapses generated in our rescue experiment were studied prospectively. Again, neither the basal (mRFP 1 /Hras mut Wnt1 low ) nor the luminal (mRFP 2 /Hras wt Wnt1 high ) subsets reconstituted tumours efficiently, whereas a 1:1 admixture of both sorted populations reliably reconstituted biclonal tumours (Extended Data Fig. 7) . Notably, every tumour reconstituted in these experiments faithfully restored the subclonal composition of the source tumour, pointing to strong selection favouring propagation of both subclones in tandem.
iWnt tumours that regress upon Dox withdrawal frequently relapse weeks later as Dox-independent tumours (DITs), mirroring the clinical scenario of acquired resistance to effective targeted therapy. Next, we asked which subclone(s) contribute when biclonal tumours beget relapse. A putative biclonal iWnt tumour with an Hras MAF ,0.3 was identified and propagated on host mice, generating a set of Dox-dependent tumour explants. Explants maintained the Hras MAF observed in the parental tumour, suggesting a stable biclonal configuration (Fig. 4a, b ). Host mice were then subjected to Dox withdrawal and monitored until relapse, generating a set of 20 DITs. In accord with our previous work 28 , 18 of the 20 relapses (90%) occurred through one of two mutually exclusive modes of Wnt pathway reactivation. Seven DITs (35%) re-expressed the Wnt1 transgene, and all seven had acquired one of two rtTA mutations (G138R or H100Y) previously shown to rescue mammary tumours from oncogene withdrawal by enabling aberrant, Dox-independent expression of TetO-controlled transgenes 29 . All seven of these tumours had an Hras MAF comparable to parental tumour (Fig. 4b) , strongly suggesting that rtTA mutations originating within the Hras wt subclone restored both Wnt1 expression and cooperation with Hras mut cells, culminating in biclonal relapse.
Eleven DITs (55%) instead rescued oncogenic signalling by acquiring an activating mutation in the b-catenin gene (Ctnnb1, hereafter bcat), a key downstream Wnt effector (Fig. 4a, b ). Compared with parental tumour, these relapses showed markedly increased Hras MAFs that were highly reproducible across the tumour set ( Fig. 4b) . Therefore, bcat mutations probably originated within Hras mut cells that later emerged as predominant relapse clones. By activating the Wnt pathway in a cellautonomous manner, bcat mutations presumably obviated the need to maintain cooperation with Wnt-producing Hras wt subclones. As such, bcat mut relapse clones act like 'defectors' in evolutionary game theory terms. Hras MAFs in bcat mut relapses consistently exceeded 0.5, indicating that bcat mut clones must harbour additional Hras locus aberrations; however, no gross changes in Hras gene copy number were observed 
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(Extended Data Fig. 8 ), implicating copy-number-neutral loss-ofheterozygosity events.
To further examine the clonal configuration of relapsed tumours, an iWnt/mRFP 1 tumour previously confirmed as biclonal in our rescue experiments (Fig. 2 ) was propagated as above to derive DITs, then relapsederived tumour cells were separated into basal and luminal subsets and analysed. One DIT that relapsed via Wnt1 transgene re-expression was biclonal with a luminally restricted rtTA mutation (Fig. 4c ). Trophic support from this luminal rtTA mut subclone probably rescued growth of its basal rtTA wt counterpart, providing a plausible cellular mechanism whereby this rescue mutation was maintained at a low MAF. By contrast, our previous analysis indicated that bcat rescue mutations originate within basal tumour cells and obviate the need to cooperate with Wnt-producing luminal cells. Nonetheless, bcat mut relapses consistently harboured abundant luminal tumour cells ( Fig. 4c and Extended Data Fig. 9 ). We proposed that acquired bcat mutations endow basally restricted subclones with novel bipotent differentiation potential, thereby converting them to hierarchically configured clones at relapse. Two bcat mut DITs analysed as above showed comparable bcat mut allele prevalence in the basal and luminal subsets (Fig. 4c ), consistent with a scenario in which bcat mut relapse clones acquired bipotency. (An alternative scenario in which each subclone independently acquired matching bcat mutations cannot be formally excluded, but seems less likely.) In our previous experiments ( Fig. 2 and Extended Data Fig. 4 ) and in the rtTA mut relapse profiled above, this same subclone invariably behaved in a unipotent manner, remaining basally restricted when partnered with a Wnt1-expressing luminal subclone in the context of primary and relapsed tumours.
Efforts to explain how some cancers stably maintain intratumoral lineage diversity typically invoke tumour cell hierarchies. Here we show that cooperation between lineage-restricted subclones provides an alternative mechanism for maintaining tumour cell heterogeneity. In our Wnt models, we found evidence for both hierarchically and biclonally configured tumours, yet differently configured tumours were indistinguishable by histopathology, acquired equivalent cooperating Hras mut alleles (albeit with differences in tumour cell compartmentalization), and were comparably Wnt1 dependent. Thus, although distinct clonal configurations evolved, they converged towards analogous malignant phenotypes. These findings highlight the difficulties associated with inferring the clonal architecture of cancers from histopathology, even in the 'simplified' context of mouse models. Notably, the Wnt models described here provide an experimentally tractable system for exploring whether and how a tumour's clonal configuration determines its clinical behaviour and curability.
Our study does not define when distinct subclones emerge in the course of tumour progression. Interclonal cooperation may be particularly prevalent in tumours initiated by aberrant expression of secreted signalling molecules, such as Wnt1 and platelet-derived growth factor 30 . In principle, germline mutations that impart a cancer predisposition also might bias tumours towards a biclonal configuration, as any subsequent cooperation-enabling mutations would necessarily accrue in a cell with mutant neighbours. As such, it will be important to determine whether interclonal cooperation can arise when initiating events originate in somatic cells or act primarily in a cell-intrinsic manner. If cooperation emerges as a common mechanism for maintaining subclone diversity in malignancies, this scenario would counter a key assumption made when interpreting cancer genome sequences. Specifically, certain mutations detected at low allelic fractions and commonly assumed to be late events in tumour progression instead may be early events that enable interclonal cooperation.
METHODS SUMMARY
The MMTV-Wnt1 (FVB.Cg-Tg(Wnt1)1Hev/J; stock no. 002934) and mRFP (B6.Cg-Tg(CAG-mRFP1)1F1Hadj/J; stock no. 005884) transgenic lines were obtained from subclone. a, DNA sequencing chromatograms depicting matching Hras CAA61CGA mutations detected in primary and relapsed tumours, with an increased MAF detected in the setting of a bcat mutation. b, Bottom, histogram depicting MAFs for a series of primary and relapsed tumours derived from a parental biclonal tumour. Top, corresponding gene expression patterns for each tumour by northern hybridization analysis. c, DNA sequencing chromatograms depicting matching Hras GGA12GAA mutations detected in primary and relapsed tumours, with an increased MAF detected in the setting of a bcat mutation. Panels on the right depict analysis of unsorted and sorted cells at relapse showing unipotent or bipotent mutant subclones, depending on the mode of Wnt pathway reactivation. d, Histogram showing Wnt1 expression levels relative to Gapdh in unsorted and sorted tumour cells from a bcat mut rtTA wt relapse versus a bcat wt rtTA mut relapse with the value measured in unsorted cells from the latter relapse set at 1.
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the Jackson Laboratories. The MMTV-rtTA and tetO-Wnt1 transgenic lines were a gift from L. Chodosh. All mice either were generated in an inbred FVB/N background or were backcrossed ten or more generations with FVB/N breeders before initiating experiments. To determine Hras MAFs, we measured peak height (PH) attributable to mutant and wild-type alleles on DNA sequencing chromatograms using ImageJ 1.46 software, then calculated Hras MAF values using the following formula: MAF 5 PH mutant / (PH mutant 1 PH wild-type ). Mammary tumours were dissociated into single-cell suspensions and processed for immunostaining and FACS as previously described 24 . Tumour cells were re-suspended in a 50% solution of Matrigel in PBS before mammary fat pad injection.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Transgenic mice. Mice were housed under pathogen-free conditions in the Pennsylvania State University College of Medicine rodent facility with access to water and chow ad libitum. All experimental protocols were approved by the Pennsylvania State University College of Medicine's Institutional Animal Care and Use Committee. The MMTV-Wnt1 (FVB.Cg-Tg(Wnt1)1Hev/J; stock no. 002934) and mRFP (B6.Cg-Tg(CAG-mRFP1)1F1Hadj/J; stock no. 005884) transgenic lines were obtained from the Jackson Laboratories. The MMTV-rtTA and tetO-Wnt1 transgenic lines were a gift from L. Chodosh. All mice were either generated in an inbred FVB/N background or backcrossed ten or more generations with FVB/N breeders before initiating experiments. Dox was administered by replacing standard mouse chow with chow containing 2 g kg 21 Dox (Bio-Serv). Genotyping was performed by PCR using genomic DNA isolated from tail clips and transgene specific primers (available upon request). Cell sorting. Mammary tumours were dissociated into single-cell suspensions through mechanical separation and enzymatic digestion as described 22 . Dissociated tumour cells were enriched for Lin 2 (CD45 2 CD31 2 TER119 2 BP-1 2 ) mammary epithelial cells with StemCell Technologies EasySep Mouse Epithelial Cell Enrichment Kits per the manufacturer's instructions. Lin 2 cells were then incubated on ice for 20 min with anti-CD49f (a6 integrin) (BD Biosciences 555734) together with Alexa Fluor 647 (Invitrogen A21247) in PBS. Cells were spun down for 5 min at 550g, then incubated with EpCAM-FITC-conjugated antibody (Biolegend 118208) in PBS. Tumour cells were sorted on a BD FACS Aria cell sorter machine equipped with Diva software into their luminal (Lin 2 CD49f low EpCAM high ) and basal (Lin 2 CD49f high EpCAM low ) subpopulations. Sorted cells were collected into 15-ml conical tubes containing PBS. Genomic DNA was collected from sorted cell populations using Qiagen Blood and Tissue DNeasy spin column kit. Total RNA was collected from sorted cell populations using Qiagen RNeasy spin column kit. RNA was reversed transcribed using Invitrogen Superscript II First Strand Synthesis kit. Tumour reconstitution and propagation. In tumour reconstitution experiments, tumour cells for injection were counted using a hemocytometer and suspended at a concentration of 1,000 cells per ml in a 50% Matrigel solution in PBS (BD Biosciences Growth Factor Reduced Matrigel Matrix). 10 5 cells in 100 ml of Matrigel solution were injected directly into intact 3 or 4 mammary fat pads of anaesthetized adult female hosts, after using a small skin incision to expose the injection site. Incisions were closed with surgical clips. No randomization was performed as host mice were genetically identical, and no mice were excluded from analysis of tumour onset. Mice were monitored at least twice weekly for tumour growth by an investigator blinded to the tumour cell injection source. To generate a cohort of clonally related tumours for generating DITs, tumour fragments were explanted onto the flanks of wild-type Dox-treated host mice. Tumours were permitted to grow to a diameter of 8-10 mm, at which point mice received a single intraperitoneal injection of N-methyl-N-nitrosourea (MNU) (Sigma 50 mg kg 21 ) to accelerate tumour relapse 1 week before Dox withdrawal. Without MNU treatment, only about one-third of iWnt tumour explants relapsed during 12 months of continuous Dox withdrawal, and relapses arose after an average latency of 6 months. With MNU treatment, more than 90% of iWnt explants relapsed within 3 months of Dox withdrawal. Tumour regression and relapse was monitored at least twice weekly. Tumours were measured in two dimensions with calipers. DNA sequencing. Genomic DNA or copy DNA isolated from tumour specimens or sorted tumour cell populations was amplified by PCR using gene-specific primers (available upon request). PCR product was run out on an agarose gel, cut out and isolated using Qiagen QIAquick Gel Isolation spin column kit. Samples were subjected to Sanger sequencing using gene-specific primers on an ABI 3130XL Capillary sequencer machine. Sequence traces were analysed using AB DNA Sequencing Analysis Software v5.2 and AB Sequence Scanner v1.0. Peak height (PH) on sequencing chromatograms was measured using ImageJ 1.46 software and Hras MAF was calculated using the following formula: MAF 5 PH mutant /(PH mutant 1 PH wild-type ). Immunofluorescence. Tumour samples were fixed in 4% paraformaldehyde on ice for 2 h before being paraffin embedded. Paraffin sections (5 mm) were stained with antibodies for smooth muscle actin (SMA) and keratin 8, which label basal and luminal epithelial cells, respectively. Primary antibodies used were: rabbit anti-SMA (AbCAM 5694, 1:250) and rat anti-keratin 8 (Troma-I) (Developmental Studies Hybridoma Bank, University of Iowa, 1:250). Secondary antibodies were: biotinylated rabbit-anti-rat IgG (Dako Cytomation E0468) and biotinylated rabbit IgG (Vector BA-1000). The fluorophore was a streptavidin fluorescein (Vector SA-5001). Hoechst-33342 dye (Invitrogen H1399) was used for nuclear DNA counterstaining, and slides were visualized using a Zeiss wide-field fluorescent microscope equipped with AxioVision 4.8 software. qRT-PCR. RNA was reversed transcribed using Invitrogen Superscript II First Strand Synthesis kit. We used Taqman Gene Expression Assay mix containing unlabelled PCR primers and a FAM-labelled Taqman probe to detect expression of the following genes: Wnt1 transgene (Applied Biosystems Mm01300555_g1), keratin 8 (Krt8) (Applied Biosystems Mm00835759_m1), Gata3 (Applied Biosystems Mm00484683_m1), Muc1 (Applied Biosystems Mm00449604_m1), keratin 5 (Krt5) (Applied Biosystems Mm00503549_m1), keratin 14 (Krt14) (Applied Biosystems Mm00516876_m1), P-cadherin (Cdh3) (Applied Biosystems Mm01249209_m1) and vimentin (Vim) (Applied Biosystems Mm01333430_m1). Relative qPCR (DDC T method) was performed in triplicate using Agilent Technologies Stratagene Mx3005P detection system and analysed using Stratagene MxPro software. Gene expression levels in sorted cell populations were normalized to Gapdh transcript levels (Applied Biosystems 4352339E) and compared to the unsorted sample (relative expression 5 1). Northern hybridization. Total RNA was isolated from snap-frozen bulk tumour pieces by CsCl Density Gradient Centrifugation. Northern hybridization was performed as described previously 28 using cDNA probes generated by RT-PCR. Primer pairs for probes are as follows: Wnt1, forward 59-TGCGGTTCCTGTATTTTGC-39 and reverse 59-TGCATTCCTTTGGCGAGAGG-39; Axin2, forward 59-CCGAG CTCATCTCCAGGC-39 and reverse 59-GGACAGAGGCAGCGGACTC-39; b-actin (Actb), forward 59-TGAGACCTTCAACACCCCAG-39 and reverse 59-TGAGA CCTTCAACACCCCAG-39. After subcloning, the identity of each probe was confirmed by DNA sequence analysis. a, Tumours reconstituted on wild-type or cWnt hosts following injection of iWnt/mRFP 1 tumour cells were subjected to Dox withdrawal and monitored for regression. *Shown as number of tumour regressions per number of tumours subjected to Dox withdrawal. b, Northern hybridization analysis of tumour RNA with Wnt1 probe. Tumours were reconstituted on Dox-treated cWnt hosts following injection of iWnt/mRFP 1 tumour cells. Depicted below are the corresponding FACS plots showing the range of contributions by donor-derived mRFP 1 and host-derived mRFP 2 cells to reconstituted tumours before Dox withdrawal. Colours indicate events within the basal (blue; CD49f high EpCAM low ) and luminal (green; CD49f low EpCAM high ) gates. On rescue hosts, primary tumours that arose during Dox treatment incorporated a variable number of cWnt luminal cells, indicating that the crosstalk between heterologous cells required to seed relapse sometimes occurs early in tumour reconstitution. For one of three primary tumours analysed, the conversion to lineage-restricted chimaerism and cWnt transgene expression was essentially complete, meaning that cWnt-producing cells had replaced iWnt-producing cells despite ongoing Dox treatment. Analysis of this tumour required necropsy of the host, precluding determination of its clinical response to Dox withdrawal, which we propose would have been negligible. Concordantly, in rare cases the growth of sibling primary tumours propagated on rescue hosts continued unimpeded by Dox withdrawal, and these tumours always showed pronounced, lineage-restricted chimaerism at necropsy. Elucidating mechanisms whereby host cWnt cells compete with luminal iWnt tumour cells to become the predominant Wnt-producing subclone may offer new insights into evolutionary forces shaping tumour microenvironments.
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Extended Data Figure 5 | Basal subclones from two additional iWnt/ mRFP 1 tumours rescued from Dox withdrawal by heterologous cWnt host cells. a, Growth curves of tumour outgrowths derived from an iWnt/mRFP 1 tumour harbouring a basally restricted Hras GGA12AGA mutation. Curves depict regression and relapse of tumours reconstituted on cWnt rescue hosts following Dox withdrawal. b, c, Top, representative FACS plots showing contributions from donor-derived mRFP 1 cells and host-derived mRFP 2 cells during tumour reconstitution. Colours indicate events within the basal (blue; CD49f high EpCAM low ) and luminal (green; CD49f low EpCAM high ) gates.
Bottom, DNA sequencing chromatograms showing matching, basally restricted Hras mutations present in both primary Dox-dependent tumours and chimaeric Dox-independent relapses. d-f, Data panels presented as in a-c, showing similar results for an independent iWnt/mRFP 1 tumour harbouring a distinct, basally restricted Hras CAA61CGA mutation. For both tumours shown here, northern hybridization analysis confirmed expression of donor-derived iWnt transgene before Dox withdrawal, followed by a switch to expression of host-derived cWnt transgene at relapse (data not shown).
